Ssu-Hsueh Tseng
Overview
Explore the profile of Ssu-Hsueh Tseng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
220
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Anchoori R, Tseng S, Tsai H, Palande V, Rudek M, Roden R
PLoS One
. 2024 Jul;
19(7):e0305710.
PMID: 38990850
There is an urgent unmet need for more targeted and effective treatments for advanced epithelial ovarian cancer (EOC). The emergence of drug resistance is a particular challenge, but small molecule...
2.
Tu H, Wong M, Tseng S, Ingavat N, Olczak P, Notarte K, et al.
J Ovarian Res
. 2024 Jan;
17(1):19.
PMID: 38225646
Background: MUC16 is a heavily glycosylated cell surface mucin cleaved in the tumor microenvironment to shed CA125. CA125 is a serum biomarker expressed by > 95% of non-mucinous advanced stage...
3.
Lam B, Kung Y, Lin J, Tseng S, Tu H, Huang C, et al.
J Clin Invest
. 2023 Nov;
134(1).
PMID: 37917174
Even with the prolific clinical use of next-generation cancer therapeutics, many tumors remain unresponsive or become refractory to therapy, creating a medical need. In cancer, DCs are indispensable for T...
4.
Anchoori R, Anchoori V, Lam B, Tseng S, Das S, Velasquez F, et al.
PLoS One
. 2023 Jun;
18(6):e0285221.
PMID: 37315065
Bortezomib has been successful for treatment of multiple myeloma, but not against solid tumors, and toxicities of neuropathy, thrombocytopenia and the emergence of resistance have triggered efforts to find alternative...
5.
Kung Y, Lam B, Tseng S, MacDonald A, Tu H, Wang S, et al.
J Biomed Sci
. 2022 Aug;
29(1):57.
PMID: 35962391
Background: For centuries, microbial-based agents have been investigated as a therapeutic modality for the treatment of cancer. In theory, these methods would be cheap to produce, broadly applicable in a...
6.
Tseng S, Cheng M, Farmer E, Ferrall L, Kung Y, Lam B, et al.
J Immunother Cancer
. 2022 Apr;
10(4).
PMID: 35459734
Background: Type I interferons (IFN) promote dendritic cells maturation and subsequently enhance generation of antigen-specific CD8 +T cell for the control of tumor. Using type I interferons as an adjuvant...
7.
Lam B, Kung Y, Lin J, Tseng S, Tsai Y, He L, et al.
Cell Rep
. 2021 Oct;
37(3):109838.
PMID: 34648735
As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spreads, variants with enhanced virulence and transmissibility have emerged. Although in vitro systems allow rapid characterization, they do not fully recapitulate the...
8.
Tseng S, Liu L, Peng S, Kim J, Ferrall L, Hung C, et al.
J Biomed Sci
. 2021 Sep;
28(1):63.
PMID: 34517865
Background: Human Papillomavirus type 16 (HPV16) has been associated with a subset of head and neck cancers. Two HPV encoded oncogenic proteins, E6 and E7, are important for the malignant...
9.
Anchoori R, George L, Tseng S, Lam B, Polkampally S, Amiano A, et al.
PLoS One
. 2021 Sep;
16(9):e0256937.
PMID: 34506530
Bortezomib and the other licensed 20S proteasome inhibitors show robust activity against liquid tumors like multiple myeloma, but have disappointed against solid tumors including ovarian cancer. Consequently, interest is mounting...
10.
Mao C, Wang S, Su Y, Tseng S, He L, Wu A, et al.
Sci Adv
. 2021 Aug;
7(33).
PMID: 34380620
The ability to characterize individual biomarker protein molecules in patient blood samples could enable diagnosis of diseases at an earlier stage, when treatment is typically more effective. Single-molecule imaging offers...